How many patients with transthyretin amyloid cardiomyopathy (or ATTR-CM) are still hiding in plain sight in our clinics? Too often, the challenge is not confirming the diagnosis but suspecting it early enough.
Following on from a recent interactive Experts Knowledge Share webinar, this suite of resources brings together clinical insight and patient perspective to help close that gap.
Cardiologist Dr Philippe Debonnaire (Belgium) joined patient advocate Keith Dares (Canada), who lives with ATTR-CM himself, to help create this comprehensive educational programme.
Explore this collection of resources, as two experts discuss the recognition and diagnosis of ATTR-CM from both clinical and patient perspectives.
You'll hear about the red flags that should raise suspicion, the current diagnostic pathway and tools available today, and the barriers that can delay diagnosis in real-world practice.
This is the full webinar replay. Watch the highlights from the conversation in the Highlights tab, or scroll down for the podcast and HCP infographic and patient infographic to use in your practice.
Clinical takeaways
- ATTR-CM is under-recognised and frequently misdiagnosed, resulting in delayed diagnosis and treatment initiation
- Recognising the red flags of ATTR-CM is essential for referral and for establishing diagnosis using the diagnostic algorithm
- Early diagnosis includes screening in at-risk populations
